Markets:

Overview

News

Currencies

International

Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

29.06 -0.31 (-1.06%)

Streaming Delayed Price Updated: 10:12 AM EDT, May 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2023 ↗

March 24, 2023

Via Benzinga

Legend Biotech Announces Participation in Upcoming Investor Conferences

February 24, 2023

From Legend Biotech

Via Business Wire

Legend Biotech Regains Compliance with NASDAQ Listing Rule 5250(c)(2)

February 21, 2023

From Legend Biotech

Via Business Wire

Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug ↗

January 28, 2023

Shanghai’s HutchMed out-licensed global rights for a colorectal cancer therapy to Japan’s Takeda in a deal worth up to $1.13 billion, including $400 million upfront. In addition to the $1.13 billion,...

Via Talk Markets

The Latest Analyst Ratings for Legend Biotech ↗

January 24, 2023

Via Benzinga

4 Analysts Have This to Say About Legend Biotech ↗

December 20, 2022

Via Benzinga

Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI® (ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

January 27, 2023

From Legend Biotech

Via Business Wire

Legend Biotech to Participate in the 41st Annual JP Morgan Healthcare Conference

January 03, 2023

From Legend Biotech

Via Business Wire

Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China

January 02, 2023

From Legend Biotech

Via Business Wire

Gracell Biotech Stock Has Over 100% Upside On Next-Gen CAR-T Platforms, Analyst Claims ↗

December 08, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022 ↗

December 06, 2022

Via Benzinga

Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer

November 21, 2022

From Legend Biotech

Via Business Wire

Legend Biotech Announces Participation in Upcoming Investor Conferences

November 04, 2022

From Legend Biotech

Via Business Wire

Legend Biotech Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Program at ASH 2022

November 03, 2022

From Legend Biotech Corporation

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022 ↗

November 02, 2022

Upgrades

Via Benzinga

Carnival, Amazon, Iamgold And Other Big Gainers From Tuesday ↗

October 19, 2022

U.S. stocks closed higher on Monday, with the Dow Jones gaining more than 300 points. Here is the list of some big stocks recording gains in the previous session.

Via Benzinga

Why Legend Biotech's Shares Jumped 14.2% On Tuesday ↗

October 18, 2022

The company presented news regarding early revenue figures for a multiple myeloma therapy it collaborated on.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022 ↗

November 01, 2022

Upgrades

Via Benzinga

Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors

September 29, 2022

Via AB Newswire

Why Quoin Pharmaceuticals Shares Jumped By More Than 44%; Here Are 57 Biggest Movers From Yesterday ↗

October 19, 2022

Gainers COMSovereign Holding Corp. (NASDAQ: COMS) shares jumped 170.1% to close at $0.1194 on Tuesday after gaining 4% on Monday.

Via Benzinga

CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

September 27, 2022

From Legend Biotech Corporation

Via Business Wire

Legend Biotech to Host 2022 R&D Day on Monday, October 3, 2022

September 15, 2022

From Legend Biotech Legend Biotech Corporation

Via Business Wire

No Early Relief for JW Therapeutics from Cancer Wonder Drug ↗

September 07, 2022

Key Takeaways: JW Therapeutics prices its new cancer therapy at around a million yuan, with the high production costs hard to bring down. Large-scale market expansion is not going to be easy The...

Via Benzinga

Legend Biotech Stock Joins Elite Club Of Stocks With RS Ratings Over 90 ↗

September 01, 2022

On Thursday, Legend Biotech stock had its Relative Strength (RS) Rating upgraded to 91, up from 87 a day earlier.

Via Investor's Business Daily

Legend Biotech Announces Participation in Upcoming Investor Conferences

August 19, 2022

From Legend Biotech

Via Business Wire

NexImmune Pauses Developing Multiple Myeloma Hopeful, Citing Competition ↗

August 16, 2022

NexImmune Inc (NASDAQ: NEXI) cited the competitive environment in the blood cancer space as the reason for

Via Benzinga

Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2022

August 05, 2022

From Legend Biotech Corporation

Via Business Wire

Legend Biotech Appoints Three New Directors and Elects New Chairman of the Board

August 04, 2022

From Legend Biotech

Via Business Wire

Week In Review: China Biopharma Tops $2.8 Billion In Week's Dealmaking ↗

July 30, 2022

CSPC Pharma out-licensed global rights for its antibody drug conjugate targeting Claudin18.2 to Elevation Oncology of New York City. CSPC will receive a $27 million upfront payment and up to $148...

Via Talk Markets

PayPal, Alphabet And Some Other Big Stocks Recording Gains On Wednesday ↗

July 28, 2022

U.S. stocks closed sharply higher on Wednesday, with the Dow Jones jumping more than 400 points. Here is the list of some big stocks moving higher in the previous session.

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.